GlassScriptPhysician profile
Michael Hahalyak
NPI 1306889605
$9,150.13
in general payments reported to CMS, 2019-2025
36 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,535 · 2020: $1,201 · 2021: $1,214 · 2022: $996 · 2023: $1,243 · 2024: $1,538 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,204.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,188.99 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $950.16 | 2019-2025 | |
| Abbvie INC. | $833.65 | 2019-2024 | |
| Novo Nordisk INC | $791.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $563.04 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $518.38 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $490.07 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $483.88 | 2019-2025 | Trintellix |
| Daiichi Sankyo INC. | $327.39 | 2019-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.41 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $250.35 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $232.34 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $196.45 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $132.31 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $100.23 | 2019-2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hahalyak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.